173 related articles for article (PubMed ID: 29899839)
1. A novel
Primo D; Scarfò L; Xochelli A; Mattsson M; Ranghetti P; Espinosa AB; Robles A; Gorrochategui J; Martínez-López J; de la Serna J; González M; Gil AC; Anguita E; Iraheta S; Munugalavadla V; Quéva C; Tannheimer S; Rosenquist R; Stamatopoulos K; Ballesteros J; Ghia P
Oncotarget; 2018 May; 9(40):26019-26031. PubMed ID: 29899839
[TBL] [Abstract][Full Text] [Related]
2. Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
Barrientos JC
Future Oncol; 2016 Sep; 12(18):2077-94. PubMed ID: 27324214
[TBL] [Abstract][Full Text] [Related]
3. Cell lines generated from a chronic lymphocytic leukemia mouse model exhibit constitutive Btk and Akt signaling.
Singh SP; Pillai SY; de Bruijn MJW; Stadhouders R; Corneth OBJ; van den Ham HJ; Muggen A; van IJcken W; Slinger E; Kuil A; Spaargaren M; Kater AP; Langerak AW; Hendriks RW
Oncotarget; 2017 Sep; 8(42):71981-71995. PubMed ID: 29069762
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.
Göckeritz E; Kerwien S; Baumann M; Wigger M; Vondey V; Neumann L; Landwehr T; Wendtner CM; Klein C; Liu N; Hallek M; Frenzel LP; Krause G
Int J Cancer; 2015 Nov; 137(9):2234-42. PubMed ID: 25912635
[TBL] [Abstract][Full Text] [Related]
5. Treatment with idelalisib in patients with chronic lymphocytic leukemia - real world data from the registry of the German CLL Study Group.
von Tresckow J; Heyl N; Robrecht S; Giza A; Aldaoud A; Schlag R; Klausmann M; Linde H; Stein W; Schwarzer A; Fischer K; Cramer P; Eichhorst B; Hallek M; Fink AM
Ann Hematol; 2023 Nov; 102(11):3083-3090. PubMed ID: 37358640
[TBL] [Abstract][Full Text] [Related]
6. [Chronic lymphocytic leukemia].
Aoki S
Rinsho Ketsueki; 2016 Mar; 57(3):238-48. PubMed ID: 27076234
[TBL] [Abstract][Full Text] [Related]
7. Current Treatment of Chronic Lymphocytic Leukemia.
Jamroziak K; Puła B; Walewski J
Curr Treat Options Oncol; 2017 Jan; 18(1):5. PubMed ID: 28185174
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
[TBL] [Abstract][Full Text] [Related]
9. BCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic Leukemia.
Falchi L; Baron JM; Orlikowski CA; Ferrajoli A
Mediterr J Hematol Infect Dis; 2016; 8(1):e2016011. PubMed ID: 26977270
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells.
Purroy N; Carabia J; Abrisqueta P; Egia L; Aguiló M; Carpio C; Palacio C; Crespo M; Bosch F
Oncotarget; 2017 Jan; 8(1):742-756. PubMed ID: 27888629
[TBL] [Abstract][Full Text] [Related]
11. In Chronic Lymphocytic Leukemia the JAK2/STAT3 Pathway Is Constitutively Activated and Its Inhibition Leads to CLL Cell Death Unaffected by the Protective Bone Marrow Microenvironment.
Severin F; Frezzato F; Visentin A; Martini V; Trimarco V; Carraro S; Tibaldi E; Brunati AM; Piazza F; Semenzato G; Facco M; Trentin L
Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31817171
[TBL] [Abstract][Full Text] [Related]
12. BCR pathway inhibition as therapy for chronic lymphocytic leukemia and lymphoplasmacytic lymphoma.
Wiestner A
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):125-34. PubMed ID: 25696845
[TBL] [Abstract][Full Text] [Related]
13. RPPA-based protein profiling reveals eIF4G overexpression and 4E-BP1 serine 65 phosphorylation as molecular events that correspond with a pro-survival phenotype in chronic lymphocytic leukemia.
Shull AY; Noonepalle SK; Awan FT; Liu J; Pei L; Bollag RJ; Salman H; Ding Z; Shi H
Oncotarget; 2015 Jun; 6(16):14632-45. PubMed ID: 25999352
[TBL] [Abstract][Full Text] [Related]
14. Targeting PI3Kδ: emerging therapy for chronic lymphocytic leukemia and beyond.
Wei M; Wang X; Song Z; Jiao M; Ding J; Meng LH; Zhang A
Med Res Rev; 2015 Jul; 35(4):720-52. PubMed ID: 25763934
[TBL] [Abstract][Full Text] [Related]
15. Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells.
Modi P; Balakrishnan K; Yang Q; Wierda WG; Keating MJ; Gandhi V
Oncotarget; 2017 Mar; 8(10):16259-16274. PubMed ID: 28187444
[TBL] [Abstract][Full Text] [Related]
16. Targeting chronic lymphocytic leukemia cells in the tumor microenviroment: A review of the in vitro and clinical trials to date.
Crassini K; Mulligan SP; Best OG
World J Clin Cases; 2015 Aug; 3(8):694-704. PubMed ID: 26301230
[TBL] [Abstract][Full Text] [Related]
17. Targeting of HSP70/HSF1 Axis Abrogates In Vitro Ibrutinib-Resistance in Chronic Lymphocytic Leukemia.
Frezzato F; Visentin A; Severin F; Pizzo S; Ruggeri E; Mouawad N; Martinello L; Pagnin E; Trimarco V; Tonini A; Carraro S; Pravato S; Imbergamo S; Manni S; Piazza F; Brunati AM; Facco M; Trentin L
Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771616
[TBL] [Abstract][Full Text] [Related]
18. Neutralization of B-Cell Activating Factor (BAFF) by Belimumab Reinforces Small Molecule Inhibitor Treatment in Chronic Lymphocytic Leukemia.
Tandler C; Schmidt M; Heitmann JS; Hierold J; Schmidt J; Schneider P; Dörfel D; Walz J; Salih HR
Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 32977449
[TBL] [Abstract][Full Text] [Related]
19. Macitentan, a double antagonist of endothelin receptors, efficiently impairs migration and microenvironmental survival signals in chronic lymphocytic leukemia.
Maffei R; Fiorcari S; Vaisitti T; Martinelli S; Benatti S; Debbia G; Rossi D; Zucchini P; Potenza L; Luppi M; Gaidano G; Deaglio S; Marasca R
Oncotarget; 2017 Oct; 8(52):90013-90027. PubMed ID: 29163807
[TBL] [Abstract][Full Text] [Related]
20. Novel Therapies for Chronic Lymphocytic Leukemia: A Canadian Perspective.
Owen C; Assouline S; Kuruvilla J; Uchida C; Bellingham C; Sehn L
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):627-634.e5. PubMed ID: 26416145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
